Abbott’s mechanical circulatory support device, HeartMate 3 LVAD, is tailored for individuals with advanced heart failure. The device is used for both short- and long-term support in these patients.

Abbott is the maker of the HeartMate 3™ LVAD, which is the only LVAD currently approved in the U.S. Having Abbott assist with many different facets of the Phase 3 TECH-LVAD trial is going to be ...

Abbott’s HeartMate 3™ LVAD is a mechanical circulatory support device designed for patients with advanced heart failure. Abbott’s heart pumps have set the standard in LVAD therapy.

Under the Agreement, Abbott will share insights from recent ... to evaluate tecarfarin in combination with the HeartMate 3(TM) LVAD, advancing our commitment to bringing forward the first ...

Abbott is the maker of the HeartMate 3™ LVAD, which is the only LVAD currently approved in the U.S. In February 2025, Cadrenal conducted a Type D meeting with the U.S. FDA at which time the ...

Abbott will provide support in various aspects of the trial, including planning, site identification, and sharing insights from their HeartMate 3™ experiences. The LVAD market, where Abbott’s ...

Under the agreement, Abbott will share insights from recent HeartMate 3™ clinical trials and will ... research in multiple indications, including LVAD, reinforcing Cadrenal’s commitment ...

a drug intended for patients with left ventricular assist devices (LVADs). This collaboration aims to leverage Abbott’s experience with HeartMate 3™ LVAD trials to enhance trial design and patient ...